• Mashup Score: 0
    Clinical implications of neoadjuvant immunotherapy in CSCC - 6 month(s) ago

    Charlotte Zuur, Leiden University Medical Center, Leiden, The Netherlands, discusses the clinical implications of the MATISSE trial (NCT02760498) for patients with cutaneous squamous cell carcinoma (CSCC). The trial results principally evaluated whether patients with a deep response to neoadjuvant immunotherapy might be spared intensive standard-of-care surgery and radiotherapy. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      Charlotte Zuur from @LUMC_Leiden sheds light on the MATISSE trial's impact, offering potential alternatives to intensive treatments for cutaneous squamous cell carcinoma: ➡️https://t.co/T0RD9RzpWu⬅️ #ASCO23 #CTSM #SkcSM

  • Mashup Score: 0
    Nonmelanoma Skin Cancers May Have Higher Mortality Rate Than Melanoma - The ASCO Post - 6 month(s) ago

    Nonmelanoma skin cancer may be causing a greater number of global deaths than melanoma, according to findings presented by Salah et al at the European Academy of Dermatology and Venerology Congress 2023. Investigators also suggested that nonmelanoma skin cancer may be underreported and that the true impact of the disease may be higher than previously estimated. The most common types of nonmelanoma skin cancer, which develops in the upper layers of the skin, are basal cell carcinoma and squamous cell

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Nonmelanoma Skin Cancers May Have Higher Mortality Rate Than Melanoma https://t.co/WF6NmruKKi #skcsm #melsm #skincancer

  • Mashup Score: 1
    AI Software Demonstrates Potential to Accurately Detect Skin Cancer - The ASCO Post - 6 month(s) ago

    A novel artificial intelligence (AI) software may be effective in detecting skin cancer and precancerous lesions, according to findings presented by Andrew et al at the European Academy of Dermatology and Venereology Congress 2023. Skin cancer detection using AI software has rapidly improved in recent years. The first version of the AI software, tested in 2021, had a 85.9% (n = 195/227) detection rate for melanoma, 83.8% (n = 903/1,078) detection rate for all skin cancers, and 54.1% (n = 496/917) detection

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      AI Software Demonstrates Potential to Accurately Detect Skin Cancer https://t.co/aZgQ37mwdO #skcsm #skincancer #AI #oncology

  • Mashup Score: 1
    ESMO Congress 2023: Registration - 6 month(s) ago

    Individual registration is still open

    Source: www.esmo.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMO23 #Melanoma and other #skintumours Chair @TeresaSAmaral on the Track's highlights 👇Take a look at the programme to find out more on the science to expect. See you in Madrid or online 📷 Registration: https://t.co/v6UhK08FaP #melsm #skcsm https://t.co/IBuoscC43s

  • Mashup Score: 0
    Exposure to PFAS and Phenols May Be Linked to Cancer Risk - The ASCO Post - 7 month(s) ago

    PFAS has contaminated water, food, and individuals through products such as Teflon pans, waterproof clothing, stain-resistant carpets and fabrics, and food packaging. The chemicals are often referred to as forever chemicals because they don’t degrade and can last for decades in the environment. PFAS is also capable of remaining in individuals’ systems anywhere from several months to years. “These PFAS chemicals appear to disrupt hormone function in women, which is one potential mechanism that increases

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Do PFAS and Phenols Contribute to Increased Cancer Risk? https://t.co/zMBFowdBme #cancerrisk #bcsm #gyncsm #skcsm

  • Mashup Score: 0
    MATISSE: nivolumab in cutaneous squamous cell carcinoma - 7 month(s) ago

    Charlotte Zuur, Leiden University Medical Centre, Leiden, The Netherlands, outlines the primary objectives and results of the Phase II MATISSE study (NCT02760498) of nivolumab and nivolumab plus ipilimumab (two monoclonal antibodies targeting PD1 and CTLA-4 respectively) in extensive cutaneous squamous cell carcinoma (SCC). The randomised trial enrolled 40 patients with an indication for curative surgery with or without radiotherapy; the study aimed to improve patients’ clinical prospects through immunotherapy and de-escalate surgery and radiotherapy. Dr Zuur shared the promising results of the immunotherapy, stating 90% of patients who refused surgery displayed disease-free survival of 1 year. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved

    Source: www.vjoncology.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥Dr Charlotte Zuur (@LUMC_Leiden) discusses promising results from the Phase II MATISSE study using nivolumab and nivolumab plus ipilimumab in extensive cutaneous squamous cell carcinoma: ➡️https://t.co/RI7WRXGEL8⬅️ #ASCO23 #ImmunoOnc #SkcSM #CTSM #TrialUpdate

  • Mashup Score: 1
    Novel therapeutic options for PD-1 refractory melanoma - 8 month(s) ago

    Jason Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, talks on the latest developments in the PD-1-refactory melanoma space. Lifileucel, a novel tumor infiltrating lymphocyte (TIL), and RP1, an oncolytic virus, with nivolumab are both promising treatment strategies under investigation. Dr Luke additionally highlights bispecific antibodies, as well as TCR-T cells targeting PRAME. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥@jasonlukemd of @PittTweet explores PD-1-refractory melanoma advances. Lifileucel and RP1 with nivolumab, bispecific antibodies, and TCR-T cells targeting PRAME show promise in this evolving field: ➡️https://t.co/UDJ7YakfvV⬅️ #ASCO23 #MelSM #SkcSM #ImmunoOnc #CART

  • Mashup Score: 1
    Risk Factors for Melanoma Among Individuals Living in Atlantic Regions - The ASCO Post - 8 month(s) ago

    The incidence of melanoma has been rising globally. Although researchers have reported higher-than-average incidence rates of melanoma in some Atlantic regions, neighboring regions have demonstrated more average incidence rates of melanoma. In this study, the investigators compared the ultraviolet radiation exposure and protective behaviors of 7,861 participants based on their gender, income, and highest educational attainment. They found that individuals with a higher income had an increased risk of

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Risk Factors for Melanoma Among Individuals Living in Atlantic Regions https://t.co/0uqX0JlMJk #melsm #melanoma #riskfactors #skcsm

Load More